IMIsabella D'ANdrea Meira

Isabella D'ANdrea Meira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Isabella D'ANdrea Meira has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy of vagus nerve stimulator during transition to adulthood in patients with treatment‐resistant epilepsy

    by Jonadab dos Santos Silva, Shaylla Villas Boas, Henrique Januzzelli Pires Do Prado, Daniela Fontes Bezerra, Isabella D’ANdrea Meira

    Objective: To evaluate the efficacy of vagus nerve stimulation (VNS) as an adjunctive treatment in pediatric patients with treatment‐resistant epilepsy during the transition to adolescence. Methods: We performed a retrospective cohort study of 30 children (ages 2–18 years) with medication‐resistant epilepsy who underwent VNS implantation between January 2019 and January 2023 at a tertiary epilepsy center. Clinical data included demographics, epilepsy etiology and syndrome, age at implantation, seizure frequency and severity (McHugh classification), number of antiseizure medications (ASM), magnet use, and EEG findings. Outcomes were assessed at the last available follow‐up, with a minimum duration of 12 months post‐implantation. Statistical analyses comprised chi‐squared or Fisher's exact tests, Spearman rank correlation, and logistic regression; significance was set at p < 0.05. Results: At the last follow‐up, 20 of 30 patients (66.7%) achieved ≥50% reduction in seizure frequency, and 73% of patients experienced a significant decrease in seizure severity. Status epilepticus (SE) incidence fell from 67% pre‐VNS to 17% post‐VNS ( p = 0.024). The number of ASMs decreased in 57% of patients. Successful magnet activation strongly predicted responder status (OR 10.8, 95% CI 1.2–95.4; p = 0.024). Among females, 12 of 16 (75%) experienced a transient seizure worsening around menarche. Earlier VNS implantation correlated with better seizure reduction (ρ = −0.43; p = 0.015). EEG improvement—defined as reduced interictal epileptiform activity or background normalization—was observed in 23% of patients, predominantly in males and pre‐menarche females. Significance: VNS is an effective adjunctive therapy in pediatric treatment‐resistant epilepsy, yielding substantial reductions in seizure frequency and severity, lowering status epilepticus risk, and simplifying medication regimens. Pubertal status and magnet responsiveness modulate outcomes. Early VNS intervention and proactive management during adolescence may optimize therapeutic benefit.

  • Open Access

    Comprehensive insights into bone health, hormonal patterns, and fracture risks among men with drug resistant epilepsy: a crucial evaluation

    by Cristian Pieper, Leonardo Vieira Neto, Eduardo Ferreira da Gama, Francisco P. Paranhos Neto, Miguel Madeira, Laura M. Carvalho Mendonça, Isabella D’ANdrea Meira, Maria Lucia Fleiuss Farias

    Objective: To evaluate bone density and microstructure, fragility fractures, and hormones in men 50 years and older receiving antiseizure medications (ASMs). Subjects and methods: Study population included 39 men with difficult-to-control epilepsy and 42 healthy men as control group. Spine and hip areal bone mineral density (aBMD), body composition and vertebral fracture assessment (VFA) were evaluated using Dual-Energy X-Ray Absorptiometry (DXA). Volumetric bone mineral density (vBMD) and microarchitecture of trabecular and cortical compartments were evaluated using High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT). Physical activity was tested by the International Physical Activity Questionnaire (IPAQ). The fracture risk was estimated by fracture risk assessment tool (FRAX). Results: ASMs patients showed lower cortical bone thickness (Ct.Th) in distal tibia (1.196 ± 0.295 vs. 1.341 ± 0.241 mm, p = 0.03), more fractures (12 vs. 2, p = 0.003) mostly morphometric vertebral fractures, and a higher risk for major and hip fractures based on FRAX. Hormonal changes included higher median parathyroid hormone (PTH) (50.4 vs. 24 pg/mL, p < 0.001) possibly associated with vitamin D insufficiency, (25(OH)D levels below 30 ng/mL in 43.6% of ASMs patients), lower median Estradiol that was an independent factor for fractures (p = 0.04) and bioavailable Testosterone in the lowest quartile in 52 % of them. Conclusion: Men on ASMs exhibit lower Ct.Th and hormone changes that may contribute to bone fragility. While clinical fractures are infrequent, it is crucial to actively search for morphometric fractures, either during DXA or through the more available method of spine X-rays.

  • Open Access

    The reality of epilepsy in primary care in Rio de Janeiro: the importance of educational projects for better patient care

    by Vanessa Cristina Colares Lessa, Marília Bezerra Magalhães Martins, Alexandra Seide Cardoso Vidal, Leonardo Alves Araujo, Isabella D'ANdrea Meira

    Background The Basic Health Unit (Unidade Básica de Saúde – UBS, in Portuguese) is the first point of contact in the public healthcare system for people with epilepsy. Primary care professionals need to appropriately diagnose, treat, and refer, if necessary, to tertiary services. Objective To evaluate the knowledge of UBS professionals on the management of patients with epilepsy in Rio de Janeiro. Methods Online questionnaires were performed on the topic of epilepsy before and after exposure to classes taught by epileptologists. Results A total of 66 doctors participated, 54.5% of whom were residents or trained in family medicine. The majority had from 1 to 3 years of practice. Insecurity prevailed in the management of pregnant women and the elderly. Around 59.1% of the participants referred patients with seizures without examinations. A total of 78% of the participants did not correctly classify seizure types, and 2/3 did not define drug-resistant epilepsy. Induction and broad-spectrum drugs were common. The therapeutic decision depended on availability in the basic health unit (UBS) (81.8%), dosage (60.6%), side effects (34.8%), and age (36.4%). Comorbidities and sex influenced 1/4 of the sample. For 23% of the participants, the type of crisis did not affect the choice. Regarding typical non-pharmacological options, 75% of the participants were aware of cannabidiol, 40.9% of surgery, 22.7% of ketogenic diet, and 22.8% of deep brain stimulation/vagus nerve stimulation (DBS/VNS). A total of 90.2% indicated the need for training. Conclusion There are deficits in the knowledge of UBS professionals in the management of epilepsy. Specialized training is imperative to optimize the care offered within SUS.


  • Open Access

    Perspective Chapter: VNS Nerve Stimulation in Epilepsy through Lifespan

    by Isabella D’andrea-Meira

    Vagus nerve stimulation (VNS) has emerged as a significant therapeutic intervention for individuals with drug-resistant epilepsy (DRE) throughout their lifespan. DRE is a debilitating condition characterized by recurrent seizures that do not respond to traditional antiepileptic drugs, imposing substantial physical, cognitive, and emotional burdens on patients. VNS involves the implantation of a device that delivers electrical impulses to the vagus nerve, a major nerve connecting the brain to various organs. The mechanism of action is complex and not yet fully understood, but VNS has been found to modulate abnormal electrical activity in the brain, reducing the frequency and severity of seizures. This non-pharmacological approach offers a valuable alternative for patients who have exhausted conventional treatment options, improves their quality of life, and provides hope for seizure control. Importantly, VNS has demonstrated efficacy across different age groups, from children to adults, making it suitable for lifelong management of DRE. Furthermore, long-term studies have shown sustained benefits and safety of VNS, with potential positive effects on cognitive function and mood regulation. As a result, VNS represents a promising adjunctive therapy that can significantly impact the lives of individuals with drug-resistant epilepsy, offering them renewed hope and the potential for a better future.

  • Open Access

    Predictive factors for successful vagus nerve stimulation in patients with refractory epilepsy: real-life insights from a multicenter study

    by Henrique Jannuzzelli Pires Do Prado, Lécio Figueira Pinto, Daniela Fontes Bezerra, Luciano de Paola, Francisco Arruda, Andrea Julião de Oliveira, Tayla Taynan Romão, Vanessa Cristina Colares Lessa, Jonadab dos Santos Silva, Isabella D’aNdrea-Meira

    Introduction: Vagus nerve stimulation (VNS) therapy is an established treatment for patients with drug-resistant epilepsy that reduces seizure frequency by at least 50% in approximately half of patients; however, the characteristics of the patients with the best response have not yet been identified. Thus, it is important to identify the profile of patients who would have the best response to guide early indications and better patient selection.Methods: This retrospective study evaluated vagus nerve stimulation (VNS) as an adjuvant therapy for patients with drug-resistant epilepsy from six epilepsy centers in Brazil. Data from 192 patients aged 2–66 years were analyzed, and all patients received at least 6 months of therapy to be included.Results: Included patients were aged 2–66 years (25.6 ± 14.3), 105 (54.7%) males and 87 (45.8%) females. Median follow-up interval was 5 years (range, 2005—2018). Overall, the response rate (≥50% seizure reduction) after VNS implantation was 65.6% (126/192 patients). Most patients had 50–90% seizure reduction (60.9%) and nine patients became seizure-free. There were no serious complications associated with VNS implantation. The rate of a ≥ 50% seizure reduction response was significantly higher in patients with no history of neurosurgery. The presence of focal without generalized seizures and focal discharges on interictal EEG was associated with better response. Overall, etiological predictors of a better VNS response profile were tumors while a worse response to VNS was related to the presence of vascular malformations and Lennox–Gastaut Syndrome.Discussion: We observed an association between a better response to VNS therapy no history of neurosurgery, focal interictal epileptiform activity, and focal seizure pattern. Additionally, it is important to highlight that age was not a determinant factor of the response, as children and adults had similar response rates. Thus, VNS therapy should be considered in both adults and children with DRE.


  • Open Access

    Use of lacosamide in children: experience of a tertiary medical care center in Brazil

    by Tayla Taynan Romão, Abraão Iuri Medeiros Angelim, Henrique Jannuzzelli Pires Do Prado, Fernanda Veiga de Goes, Maria Elisa Paiva Pires, Rosiane da Silva Fontana, Lais de Carvalho Pires, Alexandre Ribeiro Fernandes, Isabella D'ANdrea-Meira

    Background Lacosamide (LCM) is a third-generation anti-seizure drug approved in Europe and the United States, either as a monotherapy or adjunctive therapy, to treat partial-onset seizures in adults, adolescents, and children. In Brazil, LCM is licensed for treatment only in patients older than 16 years of age. Objective To evaluate a cohort of children presenting with refractory epilepsy who received LCM as an add-on therapy and observe the response and tolerability to the LCM treatment. Methods A retrospective cohort study conducted in a tertiary health care facility, which included 26 children, aged up to 16 years, who presented with refractory epilepsy and received LCM as an add-on treatment. The follow-up visits were scheduled every 3 months until 9 months of treatment with LCM. Results After 3 months of LCM administration, in 73.1% of the children, there was a reduction of > 50% in the frequency of seizures, and this clinical improvement was maintained in most patients (73.9%) for the following 9 months. Mild (such as, somnolence and behavioral changes) or severe (seizure worsening) adverse effects were observed in two and three children respectively. Among responders to LCM, there was a higher prevalence of males, fewer concomitant anti-seizure drugs, and lower percentage of patients using sodium channel blockers. Conclusions Lacosamide should be considered as an early treatment option in pediatric patients with refractory epilepsy, mainly focal seizures.


  • Open Access

    High prevalence of psychiatric comorbidities in children and adolescents at a tertiary epilepsy center

    by Maria Antonia Serra-Pinheiro, Isabella D'ANdrea-Meira, Abraão Iuri Medeiros Angelim, Fernanda Alves Fonseca, Nicolle Zimmermann

    Background: Epilepsy is highly comorbid with psychiatric disorders and a significant amount of the morbidity related to epilepsy is in fact a result of psychiatric comorbidities. Objective: To investigate the frequency of different psychiatric comorbidities in children with refractory epilepsy. Methods: We present preliminary observational data from a series of patients (n=82) examined in the psychiatric branch of a tertiary epilepsy center in Rio de Janeiro, Brazil. Patients were classified as presenting autism spectrum disorders, mood disorders, anxiety disorders, disruptive disorders, attention deficit hyperactivity disorder (ADHD), intellectual development disorder, psychotic episode, dissociative/conversive disorders or others. We determined the frequency of each disorder, along with demographic data, medications prescribed, electroencephalogram findings and additional medical examinations and consultations. Results: The most common comorbidities in our sample were autism spectrum disorders and ADHD. Antipsychotics and selective serotonin uptake inhibitors were the most commonly prescribed psychiatric medications. Conclusions: Knowledge about the prevalence of such comorbidities may provide more targeted interventions in Psychiatry and Psychology services linked to epilepsy centers.


  • Top Cited Papers
    Open Access

    Ketogenic Diet and Epilepsy: What We Know So Far

    by Isabella D’aNdrea Meira, Tayla Taynan Romão, Henrique Jannuzzelli Pires Do Prado, Lia Theophilo Krüger, Maria Elisa Paiva Pires, Priscila Oliveira da Conceição

    The Ketogenic Diet (KD) is a modality of treatment used since the 1920s as a treatment for intractable epilepsy. It has been proposed as a dietary treatment that would produce similar benefits to fasting, which is already recorded in the Hippocratic collection. The KD has a high fat content (90%) and low protein and carbohydrate. Evidence shows that KD and its variants are a good alternative for non-surgical pharmacoresistant patients with epilepsy of any age, taking into account that the type of diet should be designed individually and that less-restrictive and more-palatable diets are usually better options for adults and adolescents. This review discusses the KD, including the possible mechanisms of action, applicability, side effects, and evidence for its efficacy, and for the more-palatable diets such as the Modified Atkins Diet (MAD) and the Low Glycemic Index Diet (LGID) in children and adults.